Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Booth

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
The Oncologist|February 10, 2024
Consuming Patients' Days: Time Spent on Ambulatory Appointments by People With CancerSana Kagalwalla, Alexander K Tsai, Manju George, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
The Lancet. Global Health|October 2, 2022
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forwardKristina Jenei, Zeba Aziz, Christopher Booth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaAlison C Young, Rachel A Craven, Dena Cohen, et al.
Gut|January 24, 2012
Cell and organ bioengineering technology as applied to gastrointestinal diseasesGiuseppe Orlando, Juan Domínguez-Bendala, Thomas Shupe, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
Nature Medicine|August 8, 2022
Choosing Wisely for oncology in Brazil: 10 recommendations to deliver evidence-based cancer careFabio Ynoe de Moraes, Gustavo Nader Marta, Gunita Mitera, et al.
The Lancet. Oncology|February 1, 2024
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi studyMegan McLeod, Julie Torode, Kari Leung, et al.
Biomaterials|May 18, 2013
Discarded human kidneys as a source of ECM scaffold for kidney regeneration technologiesGiuseppe Orlando, Christopher Booth, Zhan Wang, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The Oncologist|February 10, 2024
Consuming Patients' Days: Time Spent on Ambulatory Appointments by People With CancerSana Kagalwalla, Alexander K Tsai, Manju George, et al.
Journal of Bone Oncology|September 27, 2021
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michelle Liu, Carol Stober, et al.
The Lancet. Global Health|October 2, 2022
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forwardKristina Jenei, Zeba Aziz, Christopher Booth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaAlison C Young, Rachel A Craven, Dena Cohen, et al.
Gut|January 24, 2012
Cell and organ bioengineering technology as applied to gastrointestinal diseasesGiuseppe Orlando, Juan Domínguez-Bendala, Thomas Shupe, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
Nature Medicine|August 8, 2022
Choosing Wisely for oncology in Brazil: 10 recommendations to deliver evidence-based cancer careFabio Ynoe de Moraes, Gustavo Nader Marta, Gunita Mitera, et al.
The Lancet. Oncology|February 1, 2024
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi studyMegan McLeod, Julie Torode, Kari Leung, et al.
Biomaterials|May 18, 2013
Discarded human kidneys as a source of ECM scaffold for kidney regeneration technologiesGiuseppe Orlando, Christopher Booth, Zhan Wang, et al.
Pageof 7